Zevert 16 Tablet DT contains Betahistine 16 mg as its active ingredient, a histamine analog primarily indicated for the management of Ménière’s disease and related vestibular disorders. Betahistine acts by improving microcirculation in the inner ear, thereby reducing the frequency and severity of vertigo, tinnitus, and hearing loss associated with endolymphatic hydrops. The drug exerts its therapeutic effect through partial agonism of H1 histamine receptors and antagonism of H3 receptors, leading to vasodilation and enhanced blood flow within the labyrinthine system. Zevert 16 Tablet DT is designed as a dispersible tablet, facilitating rapid disintegration and ease of administration, particularly beneficial for patients experiencing nausea or difficulty swallowing. It is typically prescribed at a dosage of 16 mg two to three times daily, adjusted according to clinical response and tolerability. Common adverse effects may include gastrointestinal discomfort, headache, and allergic reactions, though these are generally mild and transient. Caution is advised in patients with peptic ulcer disease or asthma. Zevert 16 Tablet DT should be used under medical supervision, with regular monitoring to assess therapeutic efficacy and detect any potential adverse events. It is contraindicated in patients with hypersensitivity to Betahistine or any excipients in the formulation.